PARP inhibitors have been effective in treating homologous recombination (HR)-deficient breast and ovarian cancers based on the synthetic lethality observed between PARP inhibitors and cancer cells deficient in HR [113,114,115,116,117]. Here, PARP1 is linked to ovarian cancer.